NUVB Logo

Nuvation Bio Inc. (NUVB) 

NYSE
Market Cap
$834.45M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
68 of 776
Rank in Industry
55 of 433

Largest Insider Buys in Sector

NUVB Stock Price History Chart

NUVB Stock Performance

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an …

Insider Activity of Nuvation Bio Inc.

Over the last 12 months, insiders at Nuvation Bio Inc. have bought $3.04M and sold $0 worth of Nuvation Bio Inc. stock.

On average, over the past 5 years, insiders at Nuvation Bio Inc. have bought $6.57M and sold $33.18M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cui Xiangmin (director) — $2.32M. BLICKENSTAFF KIM D (director) — $1.5M. Mashal Robert (director) — $220,000.

The last purchase of 100,000 shares for transaction amount of $220,000 was made by Mashal Robert (director) on 2024‑10‑08.

List of Insider Buy and Sell Transactions, Nuvation Bio Inc.

2024-10-08Purchasedirector
100,000
0.0359%
$2.20$220,000+3.81%
2024-06-25Purchasedirector
277,895
0.1098%
$2.97$825,348-5.59%
2024-06-24Purchasedirector
336,874
0.1354%
$2.98$1M-4.17%
2024-06-21Purchasedirector
75,411
0.0321%
$3.00$226,233-5.57%
2024-06-20Purchasedirector
87,715
0.0372%
$2.99$262,268-4.95%
2024-06-11Purchasedirector
172,189
0.071%
$2.90$500,089+1.75%
2023-09-21Purchasedirector
53,000
0.0243%
$1.36$72,138+59.35%
2023-09-20Purchasedirector
117,100
0.0542%
$1.36$159,490+62.22%
2023-09-19Purchasedirector
5.14M
2.2462%
$1.26$6.46M+64.39%
2023-02-21Purchasedirector
53,000
0.016%
$1.36$72,138-20.39%
2023-02-20Purchasedirector
117,100
0.0339%
$1.36$159,490-20.39%
2023-02-19Purchasedirector
5.14M
1.3737%
$1.26$6.46M-20.39%
2022-12-05Purchasedirector
43,000
0.02%
$1.95$83,962-12.37%
2022-12-02Purchasedirector
47,000
0.0215%
$1.98$93,187-15.00%
2022-12-01Purchasedirector
84,959
0.0391%
$1.97$167,599-14.14%
2022-11-30Purchasedirector
75,041
0.0336%
$1.85$139,088-10.73%
2022-04-05Sale
2.5M
1.1241%
$5.60$14M-59.30%
2021-12-15Sale10 percent owner
500,000
0.2537%
$10.07$5.04M-64.26%
2021-12-07Sale10 percent owner
1.4M
0.726%
$9.80$13.72M-61.57%
2021-11-24Purchasedirector
185,026
0.0927%
$7.69$1.42M-49.16%

Insider Historical Profitability

<0.0001%
Cui Xiangmindirector
2453131
0.735%
$2.5040
BLICKENSTAFF KIM Ddirector
172189
0.0516%
$2.5010
Mashal Robertdirector
100000
0.03%
$2.5010
NODELMAN OLEGdirector
12674775
3.7973%
$2.50122<0.0001%
EcoR1 Panacea Holdings, LLC
390000
0.1168%
$2.5010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$100.96M11.2227.74M+6.15%+$5.85M0.01
Ecor1 Capital Llc$69.92M7.7719.21M0%+$00.49
Omega Fund Management Llc$51.22M5.6914.07M-6.63%-$3.64M37.97
BlackRock$45.61M5.0712.53M-2.74%-$1.29M<0.01
The Vanguard Group$27.42M3.057.53M+3%+$799,100.13<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.